The research team have developed a protein, called an antibody, that binds selectively to epithelial ovarian cancer cells. The antibody is labelled with a radioactive metal ion, the weak signal from which can be detected on a Positron Emission Tomography (PET) scan. The PET scan will show the medical team where cancer cells are within the body.
- Category
-
Trial status
Not yet recruiting
-
Trial phase
Phase 1 Drug TrialEarly stage studies seeking initial evidence of safety, dosage and efficacy in small numbers of patients or healthy volunteers.
- Registry listing
-
ERM Project ID
104284
Trial contact details
-
Contact person
Claire Jackson
-
Phone
+61 7 31636342
What you need to know
Who can take part
The trial is seeking:
- Adults (≥ 18 years)
- Histologically proven advanced ovarian cancer
What is involved for you
If you are a Mater patient, screening will take place at Mater Hospital Brisbane. All other visits will be conducted at the Royal Brisbane and Women’s Hospital.
If you are a Royal Brisbane and Women’s Hospital (RBWH) patient, all visits will be conducted at RBWH.
Your study doctor and/or a member of the research team will be scheduling your visits and you will be informed well ahead of time.
This study consists of the following hospital visits:
- Screening (up to 30 days prior to injection of the imaging agent)
- Day 0: Injection of the imaging agent, imaging, and assessments (duration approximately six hours)
- Day 2 ± 1 day: Imaging (duration approximately two hours)
- Day 5 ± 1 day : Imaging and assessments (duration approximately four hours)
- Day 7 ± 1 day: Imaging and assessments (duration approximately four hours)
Trial dates
September 2024 to September 2026
